Page last updated: 2024-08-20

2-chloroadenosine and Lymphoma, B-Cell, Marginal Zone

2-chloroadenosine has been researched along with Lymphoma, B-Cell, Marginal Zone in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buda, G; Cecconi, N; Cervetti, G; Galimberti, S; Orciuolo, E; Petrini, M; Sordi, E	1

Other Studies

1 other study(ies) available for 2-chloroadenosine and Lymphoma, B-Cell, Marginal Zone

Article	Year
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4 Topics: 2-Chloroadenosine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxyadenosines; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Remission Induction; Retrospective Studies; Rituximab; Splenic Neoplasms; Treatment Outcome	2010

Article

Year

Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).

Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

Topics: 2-Chloroadenosine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxyadenosines; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Remission Induction; Retrospective Studies; Rituximab; Splenic Neoplasms; Treatment Outcome

2010